MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$378,169K
Proceeds from issuance of
common stock under the...
$9,552K
Proceeds from exercise of
options
$4,064K
Net cash provided by
financing activities
$411,167K
Increase (decrease) in
cash, cash...
$320,248K
Canceled cashflow
$90,919K
Equity-based compensation
expense
$17,155K
Accrued expenses
$4,668K
Non-cash lease expense
$980K
Depreciation expense
$408K
Other non-current
assets
-$155K
Accounts payable
$16K
Maturities of marketable
securities
$147,895K
Net cash used in
operating activities
-$55,570K
Net cash (used in)
provided by investing...
-$35,349K
Canceled cashflow
$23,382K
Canceled cashflow
$147,895K
Net loss
-$74,111K
Purchases of marketable
securities
$183,244K
Prepaid expenses and
other current assets
$2,490K
Amortization of discounts on
marketable securities
$1,549K
Operating lease liability
-$802K
Back
Back
Cash Flow
Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics, Inc. (APGE)
source: myfinsight.com